Compare FHI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHI | LIVN |
|---|---|---|
| Founded | 1955 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | N/A | 1993 |
| Metric | FHI | LIVN |
|---|---|---|
| Price | $54.02 | $63.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $49.00 | ★ $65.00 |
| AVG Volume (30 Days) | 643.0K | ★ 656.1K |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 50.93 | N/A |
| EPS | ★ 4.77 | N/A |
| Revenue | ★ $1,742,513,000.00 | $1,348,962,000.00 |
| Revenue This Year | $10.23 | $12.25 |
| Revenue Next Year | $6.95 | $6.75 |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | ★ 8.98 | 8.63 |
| 52 Week Low | $35.05 | $32.48 |
| 52 Week High | $54.42 | $65.57 |
| Indicator | FHI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 61.02 |
| Support Level | $51.88 | $61.79 |
| Resistance Level | $53.56 | $63.32 |
| Average True Range (ATR) | 1.10 | 1.50 |
| MACD | 0.27 | -0.36 |
| Stochastic Oscillator | 91.03 | 38.85 |
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.